Literature DB >> 23084531

Advanced clinical states in prostate cancer.

Heather H Cheng1, Daniel W Lin, Evan Y Yu.   

Abstract

The classification of clinical disease states within advanced prostate cancer is set apart from other solid tumors largely through measurement of prostate-specific antigen in the blood. This testing has allowed the distinction between the castration-sensitive and the castration-resistant states, to complement radiographic distinction within advanced prostate cancer. This has paved the way for advances in prognostication and treatment of patients within a heterogeneous disease group. Currently used clinical classifications have limitations and continue to evolve. The authors define the current disease states and discuss implications for prognosis and treatment decisions, as well as the limitations of existing classifications and emerging discoveries.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23084531     DOI: 10.1016/j.ucl.2012.07.011

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  9 in total

1.  [Sanggenon C induces apoptosis of prostate cancer PC3 cells by activating caspase 3 and caspase 9 pathways].

Authors:  Ping Zhou; Xiao-Xian Dong; Ping Tang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-09-20

2.  SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.

Authors:  Evan Y Yu; Hongli Li; Celestia S Higano; Neeraj Agarwal; Sumanta K Pal; Ajjai Alva; Elisabeth I Heath; Elaine T Lam; Shilpa Gupta; Michael B Lilly; Yoshio Inoue; Kim N Chi; Nicholas J Vogelzang; David I Quinn; Heather H Cheng; Stephen R Plymate; Maha Hussain; Catherine M Tangen; Ian M Thompson
Journal:  J Clin Oncol       Date:  2015-04-06       Impact factor: 44.544

3.  Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study.

Authors:  Pedro C Barata; Matthew Cooney; Prateek Mendiratta; Allison Tyler; Robert Dreicer; Jorge A Garcia
Journal:  Invest New Drugs       Date:  2018-09-06       Impact factor: 3.850

4.  Delayed antiandrogen withdrawal syndrome after discontinuation of bicalutamide.

Authors:  Andrew J Cowan; Yoshio Inoue; Evan Y Yu
Journal:  Clin Genitourin Cancer       Date:  2014-09-22       Impact factor: 2.872

5.  Targeting Prostate Cancer Using Intratumoral Cytotopically Modified Interleukin-15 Immunotherapy in a Syngeneic Murine Model.

Authors:  Efthymia Papaevangelou; Dorota Smolarek; Richard A Smith; Prokar Dasgupta; Christine Galustian
Journal:  Immunotargets Ther       Date:  2020-07-27

Review 6.  Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer.

Authors:  Neha Gupta; Omar Al Ustwani; Li Shen; Roberto Pili
Journal:  Onco Targets Ther       Date:  2014-02-12       Impact factor: 4.147

7.  Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study.

Authors:  Luca Triggiani; Filippo Alongi; Michela Buglione; Beatrice Detti; Riccardo Santoni; Alessio Bruni; Ernesto Maranzano; Frank Lohr; Rolando D'Angelillo; Alessandro Magli; Alberto Bonetta; Rosario Mazzola; Nadia Pasinetti; Giulio Francolini; Gianluca Ingrosso; Fabio Trippa; Sergio Fersino; Paolo Borghetti; Paolo Ghirardelli; Stefano Maria Magrini
Journal:  Br J Cancer       Date:  2017-04-27       Impact factor: 7.640

8.  When to perform positron emission tomography/computed tomography or radionuclide bone scan in patients with recently diagnosed prostate cancer.

Authors:  Carmelo Caldarella; Giorgio Treglia; Alessandro Giordano; Luca Giovanella
Journal:  Cancer Manag Res       Date:  2013-06-25       Impact factor: 3.989

Review 9.  Targeting alternative sites on the androgen receptor to treat castration-resistant prostate cancer.

Authors:  Nada Lallous; Kush Dalal; Artem Cherkasov; Paul S Rennie
Journal:  Int J Mol Sci       Date:  2013-06-14       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.